Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 25,484 shares at $67.84 ($1.7M) on 2026-02-27, disclosed to the SEC on 2026-03-03.
Scheduled sale ($1.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $67.08 | 14,584 | $978K | 57.0% |
| 2 | $67.84 | 10,900 | $739K | 43.0% |
| Total | $67.41 avg | 25,484 | $1.7M | 100% |
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2025-11-14 | $3.4M | — | Filing → |